Systemic mastocytosis with associated acute myelogenous leukemia

Area of Science:

• Hematology
• Oncology

Background:

• Systemic mastocytosis (SM) involves abnormal mast cell growth.
• Many SM patients have co-existing blood disorders.
• SM-acute myeloid leukemia (SM-AML) has a poor prognosis.

Observation:

• A 62-year-old woman with SM-AML received standard induction chemotherapy (cytarabine/idarubicin) with residual disease.
• A second induction regimen (clofarabine/high-dose cytarabine) achieved AML remission, but mast cell infiltration persisted.
• Post-consolidation therapy and allogeneic stem cell transplant, bone marrow analysis revealed no blasts but approximately 5% mast cell infiltrate.

Findings:

• Aggressive chemotherapy and stem cell transplantation can induce remission in SM-AML.
• Mast cell persistence post-treatment is a notable observation in SM-AML cases.

Implications:

• This case suggests a potential therapeutic strategy for SM-AML.
• Further research is needed to understand and manage persistent mast cell populations in SM-AML survivors.
• Optimizing treatment protocols for SM-AML may improve patient outcomes.